Based on research in post-surgery patients, the FDA approved suzetrigine, a non-opioid analgesic, for the treatment of adults with moderate to severe acute pain.
Advocates for Arthritis 2025: Preview of Key Issues
When ACR volunteer leaders, members and patient advocates head to Capitol Hill in May, they will urge members of Congress to protect Medicare and Medicaid against cuts, restore research funding and reform pharmacy benefit managers for better transparency and accountability.
RheumPAC Matching Campaign Now Underway
The annual matching campaign will run through May, coinciding with the ACR’s Advocates for Arthritis event. If you have not made your 2025 donation yet, now is the best time to invest for the largest impact.
Colin Edgerton, MD, Testifies in Congressional Hearing on Biosimilars
In front of the U.S. House Ways and Means Subcommittee, Dr. Edgerton described how challenges of biosimilar costs threaten patient care and outlined several potential legislative solutions.
Calling Rheumatologist Leaders: AMA House of Delegates Opportunity
The ACR’s delegation to the American Medical Association House of Delegates is seeking ACR members who may be interested in serving as representatives to the Young Physician Section.
ACR Community Practice Council Becomes Independent Practice Subcommittee
The Community Practice Council has been renamed the Independent Practice Subcommittee and now operates as a subcommittee of the Committee on Rheumatologic Care. The group will continue its mission with an enhanced platform and visibility within the College’s governance framework.
FDA Approves Oral Solution of Colchicine to Prevent Gout Flare
The FDA approved an oral solution of colchicine for the prevention of gout flare in adults. Its dosage can be easily adjusted on the basis of patient needs.
Trends in the Use of DMARDs for Patients with JIA
Yalamanchili et al. describe how trends in disease-modifying anti-rheumatic drug (DMARD) use have evolved for insured, U.S. patients with juvenile idiopathic arthritis. Overall, the study found that from 2000 to 2022 in this patient population the use of biologic and targeted synthetic DMARDs rose, while the use of conventional synthetic DMARDs declined.
Virtual Reality: An Immersive Educational Experience
Virtual reality technology may be a unique and immersive avenue for educating patients on rheumatic conditions and their treatments, with the potential to enable more informed decision making and improve care.
Semaglutatide for Patients with Knee Osteoarthritis?
Based on decades of data from dietary and other lifestyle interventions, doctors have long known that significant weight loss can be an effective treatment for people who are overweight and have knee osteoarthritis (OA). One meta-analysis showed that OA pain, function and stiffness scores improved by 2% for every 1% in lost weight.1 But the…
- 1
- 2
- 3
- …
- 814
- Next Page »